Meghna S. Trivedi

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial

Kevin Kalinsky, Melissa Accordino, Codruța Chiuzan et al. · Journal of Clinical Oncology · 2023 · 191 citations

Medicine, Oncology, Pharmacology +17

Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer

Heather Greenlee, Katherine D. Crew, Jillian L. Capodice et al. · Breast Cancer Research and Treatment · 2016 · 125 citations · Full text

Medicine, Neurology, Oncology +12

Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy

Jason I. Griffiths, Jinfeng Chen, Patrick A. Cosgrove et al. · Nature Cancer · 2021 · 90 citations · Full text

Medicine, Molecular Biology, Oncology +17

Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer

Tizita Zeleke, Qingfei Pan, Codruța Chiuzan et al. · Nature Cancer · 2022 · 77 citations · Full text

Medicine, Oncology, Pharmacology +15

A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.

Kevin Kalinsky, Melissa Accordino, Codruța Chiuzan et al. · Journal of Clinical Oncology · 2022 · 73 citations

Medicine, Oncology, Pharmacology +17